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Weexaminedtheeﬀectoflaparoscopicadjustablegastricbanding(LAGB)onweightloss,inﬂammatorymarkers,andcomponents
of the Metabolic Syndrome (MeS) in morbidly obese adolescents and determined if those with MeS lose less weight post-LAGB
thanthosewithout.Datafrom14–18yradolescentswereobtainedatbaseline,6and12monthsfollowingLAGB.Signiﬁcantweight
loss and improvements in MeS components were observed 6months and one year following LAGB. The incidence of MeS declined
56.8%after6monthsand69.6%after12months.Therewasnosigniﬁcantdiﬀerenceinamountofweight lostpost-LAGBbetween
those with and without MeS at either timepoint. Correlations between change in weight parameters and components of MeS in
those with and without MeS at baseline were examined and found to vary by diagnostic category. LAGB is eﬀective for short-term
improvement in weight, inﬂammatory markers, and components of MeS in morbidly obese adolescents.
1.Introduction
Over the past 30 years, the prevalence of adult obesity
in the United States has doubled while that of adolescent
obesity has tripled [1]. Current estimates classify 15.5% of
US children and adolescents as overweight (body mass index
(BMI) between 85th and 95th percentile for age), 4% as
obese (BMI between 95th and 99th percentile for age), and
4% as morbidly obese (BMI ≥ 99th percentile for age).
These children are at risk of developing serious obesity-
related comorbidities such as type 2 diabetes, dyslipidemia,
hypertension, and metabolic syndrome (MeS). The necessity
for early, aggressive treatment of obesity stems from the need
to not only alleviate the medical and psychosocial comor-
bidities experienced in adolescence but also to decrease the
risk of premature mortality in adulthood.
MeS aﬀects an estimated 1/3t o1 /2o fm o r b i d l yo b e s e
adolescents [2] and likely contributes to the increased mor-
bidity and mortality seen in adulthood. Pediatric MeS, just
as adult MeS, is associated with a signiﬁcantly elevated risk
of cardiovascular disease and type 2 diabetes. Additionally,
risk of MeS in adulthood is associated with its presence in
childhood and adolescence [3, 4].
Adolescent obesity has signiﬁcant long-term conse-
quences, as there is a dose-dependent relationship between
BMI in adolescence and risk of morbidity and mortality
in adulthood [5]. Alarmingly, studies show that childhood
obesity, particularly adolescent obesity, is a key predictor of
adult obesity, and up to 77% of children will carry their
obesity into adulthood [6]. The dangers of adult obesity
include a reduction of median survival by 8–10 years in
adults with BMIs between 40 and 45kg/m2 [7].
Increasing evidence suggests that traditional nonsurgical
weight loss methods are ineﬀective and that bariatric surgery
isthemostsustainableandeﬀectivetreatmentforweightloss
in the morbidly obese [8–11]. Presently, the most common
surgicaloptionsforadolescentsareRoux-en-Ygastricbypass
and laparoscopic adjustable gastric banding (LAGB), with2 Journal of Obesity
gastric bypass comprising more than 90% of US adolescent
cases in 2003 [1]. LAGB is associated with a ﬁve- to ten-fold
lower mortality rate and three-fold lower complication rate
than gastric bypass, has the advantages of adjustability and
reversibility, and has been associated with sustained weight
lossandimprovedcomorbiditiesinadults[12].Thereislittle
long-term data on LAGB in adolescents however, since the
procedure is not FDA approved for use in individuals under
the age of 18 yrs.
While a handful of promising national and international
studies demonstrating the safety and eﬃcacy of LAGB in
morbidly obese adolescents have been published [8–11, 13–
19], few report on the eﬀects of LAGB-induced weight loss
on MeS. The aim of this study was to evaluate the eﬀects of
LAGB on weight, inﬂammatory markers, and components of
MeS in morbidly obese adolescents and to determine if those
with MeS lose less weight post-LAGB than those without as a
consequence of their preoperative metabolic derangements.
We hypothesize that LAGB will result in a signiﬁcant
amount of excess weight loss, which will be accompanied
by improvements in markers of inﬂammation as well as
in measures diagnostic of MeS. We further postulate that
MeS may represent a more advanced state of metabolic
derangement,inwhichthepatientismoreresistanttoweight
loss. Therefore, those who carry a diagnosis of MeS will lose
less weight compared to those who do not.
2. Methods
This is an IRB-approved, prospective, nonrandomized single
center study conducted under an FDA-approved Investi-
gational Device Exemption. An initial feasibility trial of
15 adolescents with followup was performed with interim
safety and eﬀectiveness data submitted to the FDA. The
FDA subsequently granted approval to implant up to 125
additional patients with evaluation and followup identical
to the initial 15. All adolescents who underwent LAGB were
entered into a database and included in the data analysis.
Subjects with 6-month (6m) and/or 12-month (12m)
post-LAGB anthropometric and/or metabolic data were
included in this report, which assessed weight, BMI, waist
circumference (WC), systolic and diastolic blood pressure
(BP) percentiles, triglycerides (TG), high-density lipoprotein
(HDL), fasting blood sugar (FBS), C-reactive protein (CRP),
% weight loss (%WL), and % excess weight loss (%EWL).
Inclusion and exclusion criteria are described in Table 1.T h e
BMI guidelines used were consistent with NIH criteria for
bariatric surgery in adults [20].
2.1. Presurgical Methods. Subjects were recruited from
among those enrolled in weight management programs at
Columbia University Medical Center (CUMC) or referred by
private pediatricians to the Center for Adolescent Bariatric
Surgery. Consent was obtained from parents or caregivers
and assent obtained from each subject. Both adolescents
and their parents or caregivers were actively involved in the
screening process, during which medical, social, psychiatric,
and weight histories were obtained. As part of the protocol,
subjects who met criteria for entry were enrolled at CUMC
in either a 6m lifestyle modiﬁcation program if they had
no prior programmatic weight loss experience or a 3m
program if they had documentation of participation in
prior programs. During this time, subjects met monthly
with a nurse practitioner/exercise specialist and a registered
dietician, one to three times with an endocrinologist, and
twice with a psychiatrist or psychologist and the pediatric
surgeon. At the end of the lifestyle modiﬁcation program,
those subjects who demonstrated active participation and
willingness to make changes were oﬀered LAGB, while those
having diﬃculty with program compliance were encouraged
to continue with medical weight management. Prior to
undergoing LAGB, baseline evaluations including anthropo-
metric measurements, fasting blood studies (comprehensive
metabolic panel, lipids, and nutrition panel), and an oral
glucose tolerance test were performed. In addition, an
electrocardiogram, chest X-ray, sleep study, and abdominal
ultrasound with attention to the liver and gallbladder were
completed for preoperative clearance. A bone age was
performed to document skeletal maturity, and a serum HCG
was carried out in females to ensure negative pregnancy.
Comorbidities were diagnosed by medical staﬀ using the
followingcriteria.DiagnosisofMeSwasmadeusingthe2003
Cook criteria for adolescents with modiﬁcation of the FBS
criteriontotheNovember2003ADAcriterionof >100mg/dl
as abnormal. Thus, we used the presence of any 3 of the
following: TG ≥ 110mg/dL, HDL ≤ 40mg/dL, FBS ≥
100mg/dL,WC (cm) ≥ 90th percentile for ethnicity, age
and sex, and BP (mmHg) ≥ 90th percentile for age, height,
and sex [21]. Hypertension was deﬁned as systolic and/or
diastolic BP greater than the 95th percentile for age, sex,
and height [22]. Dyslipidemia was deﬁned by the presence
of fasting HDL ≤ 40mg/dl, LDL ≥ 110mg/dl, TG ≥
110mg /dl, and/or total cholesterol ≥200mg/dl.
Height was measured using a stadiometer to the nearest
0.1cm; weight was measured using a digital readout scale
to the nearest 0.1kg. WC was measured at the anterior
superior iliac spine to the nearest 0.5cm. BP was measured
with an aneroid sphygmomanometer while subjects were
seated. Three readings for each of systolic and diastolic BPs
were obtained, and the average of the measurements was
used. Blood samples were obtained after an overnight fast.
Serum glucose, HDL, and TG were run on an Olympus
A42700 analyzer (Olympus America Inc, Melville NY). CRP
was measured by nephelometry using a BN2 immunoassay
(Siemens Industry, USA).
2.2. Surgical Methods. LAP-BAND (LAP-BAND System;
Allergan Corp, Santa Barbara, CA) is a silicone ring with
an adjustable inner diameter that is positioned around
the proximal stomach just distal to the gastroesophageal
junction, creating a small proximal gastric pouch. Kink-
resistant tubing connects the the band to a subcutaneous
access port. Saline can be injected into or withdrawn from
the port to adjust the diameter of the band. LAP-BAND
controls the outlet diameter of the upper stomach pouch,
limiting emptying rate and causing a feeling of early satiety
and subsequent weight loss.Journal of Obesity 3
A l ls u r g i c a lp r o c e d u r e sw e r ep e r f o r m e da tt h eM o r g a n
Stanley Children’s Hospital of New York by a pediatric
surgeon (JZ). Placement of the LAP-BAND was performed
laparoscopically with the patient under general anesthesia.
The LAP-BAND was placed using 5 trocar sites according
to the pars ﬂaccida technique, which has been described in
detail elsewhere [23]. The LAP-BAND was left empty at the
endofplacementtoallowforpostoperativeswelling.Patients
were observed in the hospital overnight, and a contrast
esophagram was performed to conﬁrm band position and
assess pouch emptying prior to discharge.
2.3.Follow-UpAssessment. Patientswereinstructedtoreturn
for followup visits for assessment of weight changes, for
nutritional advice, and for postsurgical monitoring and
adjustments at weeks 2, 4, 6, and 8, then monthly for
the initial 12m, with plans for followup at 15, 18, and
24m, and semiannually thereafter for a total of 5years.
Fasting laboratory evaluations (including comprehensive
metabolic panel, nutritional panel, lipids, and oral glucose
tolerance test) were performed at postoperative months 6
and 12 with biannual assessments intended for the next
5yrs. The ﬁrst band adjustment occurred 5–6weeks post-
LAGB. Subsequent band adjustments were tailored to the
individual’s needs, including feelings of hunger and satiety,
as well as pain with or without vomiting. The overall goal for
weight loss was 1–1.5lbs per week, which is consistent with
other studies [16, 24]. Patients were instructed to follow a
pureed diet in the ﬁrst postoperative week, a blended diet
for postoperative weeks 2–3, a soft diet for postoperative
weeks 4–6, and a well-balanced low-fat diet for postoperative
week 7 and beyond. In addition, patients were instructed to
continue physical activity, to eat 3 small meals per day, to
avoid liquids 30minutes before and 30minutes after eating,
a n dt os t o pe a t i n gw h e nf u l l .
Ideal body weight was derived by multiplying the square
of each subject’s baseline height by the BMI at the 85th
percentile for each subject’s sex and age using the CDC
growth charts (2000). There is no consensus with respect to
the optimal BMI to use when determining ideal body weight
for children and adolescents. Our goal was to have subjects
achieve a weight and BMI within normal range for their age.
While a BMI at the 85th percentile is at the uppermost limit
of normal, it is within the normal range and a realistic goal
for our study subjects. Excess weight (EW) was calculated by
subtracting ideal body weight from actual baseline weight.
%EWL was calculated by dividing the amount of weight lost
at6mor12mpost-LAGBbytheEWandmultiplyingby100.
%WLwascalculatedbydividingtheamountofweightlostat
6m or 12m post-LAGB by baseline weight and multiplying
by 100.
2.4. Statistical Analysis. Pearson correlation was used to
identify associations among changes in weight and indices
of the MeS at both 6m and 12m. Fisher’s exact test was
used to assess the change in the proportion of subjects
meeting MeS criterion at 6m and 12m. Logistic regression
with dichotomously coded MeS status (improved versus
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Figure 1: %EWL 12m post-LAGB.
unimproved) was used to assess which weight change
measure was most highly associated with change in MeS
status. Linear mixed models for repeated measures were used
to check whether average within-subject changes over time
represented statistically reliable changes from baseline. The
6mand12mcohortswereanalyzedseparately.AP-valueless
than.05 was considered statistically signiﬁcant, and data are
expressed as counts and percentages or means and standard
error of the mean (SEM). No adjustments for analysis of
multiple outcome measures were made.
3. Results
All procedures were performed laparoscopically. There
were no operative deaths. Early complications included 1
exploration for bleeding, 1 repositioning of a misplaced
band, and 1 exploration for presumed bowel obstruction
which proved to be prolonged ileus. One patient developed
aggravation of plantar fasciitis requiring analgesics and
physical therapy. There were 2 minor wound complications.
Late complications included 3 band displacements which
required laparoscopic repositioning and 5 port repositions.
No patient required band removal.
From March 2006 through June 2010, 108 adolescents
(31males, 77females) underwent LA GB. At the time of
this report, all subjects were at least 6m post-LAGB and
88 (81.5%) presented for followup. These 88 adolescents
(36 Hispanic, 13 African-American, 33 Caucasian, and 6
mixed ethnicity) had baseline age 16.8±0.1yrs, BMI45.9±
1.0kg/m2,a n dE W6 6 .9 ± 3.0kg. Thirty-seven subjects had
MeS. Mean %WL at 6m post-LAGB was 7.5±0.9%, ranging
from a loss of 24.8% to a gain of 12.7%. The mean %EWL
equaled 17.1 ± 2.2%, ranging from 86.8% of excess weight
lost to 27.3% of excess weight gained. Fifteen patients gained
weight at the 6m time point with mean weight gain of
6.1 ±1.1kg.
Sixty-two subjects (57%) provided blood work for
evaluation. Baseline and 6m post-LAGB anthropometric4 Journal of Obesity
Table 1: Patient selection criteria.
Inclusion Criteria Exclusion Criteria
– 14–18 yrs old at time of enrollment – History of prior bariatric surgery or intent to have additional
bariatric surgery in the next year
–B M I≥ 40kg/m2 or ≥ 35kg/m2 and at least 1 comorbidity – History of GI tract anomalies, severe cardiopulmonary disease,
coagulopathy, hepatic insuﬃciency or cirrhosis
– Obesity for at least 5yrs with documented attempts at diet and
medical management – History of gastric or esophageal surgery
– Bone age at least 13.5 (F) and 14.5 (M) – History of chronic aspirin and/or NSAID use
– Emotional maturity – Pregnancy or intent to become pregnant in the next year
– Use of appropriate contraception (F) – Eating disorders with self-induced vomiting
– Understanding and willingness to comply with protocol – Inability to understand the intervention and followup
(F): female; (M): male; NSAID: non-steroidal anti-inﬂammatory drug.
Table 2: Clinical characteristics and MeS variables at baseline and at 6m post-LAGB (N = 62).
Variable Timepoint
Baseline 6m post-LAGB P
†
BMI (kg/m2)4 7 .8 ±0.95 (35.7–86.2) 44.0 ±1.0 (28.6–81.9) <.0001
Weight (kg) 134.9 ±3.6 (83.9–201.7) 125.5 ±3.6 (69.4–195.5) <.0001
WC (cm) 136.1 ±2.4
∗ (107.5–188) 127.8 ±2.4 (91.8–177.5) <.0001
Systolic BP (%ile) 70.9 ±3.3# (6–100) 59.6 ±3.3 (5–99) .0056
Diastolic BP (%ile) 74.5 ±2.8# (23–100) 62.3 ±2.8 (6–99) .0015
TG (mg/dl) 1.30 ±0.10 (0.44–5.57) 1.18 ±0.10 (0.32–4.27) .065
FBS (mg/dl) 4.62 ±0.06 (3.39–6.44) 4.70 ±0.06 (3.77–5.77) NS
HDL (mg/dl) 1.09 ±0.03 (0.75–1.81) 1.12 ±0.03 (0.75–1.68) NS
CRP (mg/L) 93.3 ±10.5
∗ (2.29–440.0) 66.7 ±10.5 (3.05–363.8) .0002
Data are presented as Mean ± SEM (Range). †P-value for changes in variables between baseline and 6m post-LAGB. ∗N: 59. #N: 60.
Table 3: Clinical characteristics and MeS variables at baseline and 12m post-LAGB (N = 29).
Variable Timepoint
Baseline 12 m post-LAGB P†
BMI (kg/m2)4 8 .8 ±1.4 (35.9–65.4) 42.9 ±1.5 (27.7–65.8) <.0001
Weight (kg) 135.0 ±5.2 (94.5–198.4) 120.2 ±5.2 (68.4–167.6) <.0001
WC (cm) 135.4 ±3.6
∗ (109.5–168) 123.5 ±3.5 (87–165) <.0001
SBP (%-ile) 71.1 ±5.0 (6–98) 58.1 ±5.1 (5–100) .019
DBP (%-ile) 71.7 ±3.9 (25–100) 68.0 ±4.0 (16–98) NS
TG (mg/dl) 1.30 ±0.13 (4.97–3.15) 1.22 ±0.13# (4.07–4.38) NS
FBS (mg/dl) 4.80 ±0.11 (3.94–7.44) 4.66 ±0.11 (4.05–6.16) NS
HDL (mg/dl) 1.10 ±0.05 (0.78–1.66) 1.19 ±0.05# (0.73–1.68) .029
CRP (mg/L) 77.1 ±11.4
∗ (7.0–257.1) 53.3 ±11.4# (2.1–221.9) .024
Data are presented as Mean ± SEM (Range). †P -value for changes in variables between baseline and 12m post-LAGB. ∗N: 27. #N: 28.
Table 4: P-values for correlations among weight change measures and components of MeS at 6m post-LAGB by MeS status at baseline.
Variable No MeS (N = 51) Yes MeS (N = 37)
%EWL %WL BMI %EWL %WL BMI
WC (cm) <0.0001 0.01 <0.0001 0.0024 0.0004 0.0005
HDL (mg/dl) NS NS NS NS NS NS
TG (mg/dl) NS 0.0098 0.004 NS NS NS
CRP (mg/dl) NS NS NS NS NS NS
FBS (mg/dl) NS 0.019 0.013 NS NS NS
SBP %ile NS NS 0.06 NS NS NS
DBP %ile NS NS NS NS NS NSJournal of Obesity 5
Table 5: P-values for correlations among weight change measures and components of MeS at 12m post-LAGB by MeS status at baseline.
Variable No MeS (N = 22) Yes MeS (N = 23)
%EWL %WL BMI %EWL %WL BMI
WC (cm) <0.0001 <0.0001 <0.0001 0.043 0.009 0.002
HDL (mg/dl) NS NS NS 0.032 0.047 0.08
TG (mg/dl) NS NS NS NS NS NS
CRP (mg/dl) NS NS NS NS NS NS
FBS (mg/dl) NS 0.046 0.037 NS NS NS
SBP %ile NS NS NS NS NS NS
DBP %ile 0.067 NS 0.065 NS NS NS
data of subjects who had blood work assessed were not
signiﬁcantly diﬀe r e n tf r o mt h a to fs u b j e c t sw h od i dn o t
(data not shown). There were signiﬁcant improvements in
BMI, weight, WC, systolic and diastolic BP% iles, and CRP
(Table 2). MeS resolved in 21 of the adolescents diagnosed at
baseline (56.8%; P<. 0004). No signiﬁcant diﬀerences were
observed in %EWL, %WL, or change in BMI between those
with MeS at baseline and those without (data not shown).
Resolution of MeS did not signiﬁcantly correlate with change
in BMI, %WL, or %EWL (P = NS).
At the time of this report, 84 adolescents were at least
12m post-LAGB. Forty-ﬁve adolescents (50.6%; 17male,
28female) attended 12m followup visits. These 45 adoles-
cents (19 Hispanic, 6 African-American, 17 Caucasian, and 3
mixed ethnicity) had baseline age 17.2±0.2yrs, BMI45.8±
1.5kg/m2,a n dE W6 9 .4 ± 4.3kg. Twenty-three subjects had
MeS.The%WLforthis groupwas10.9±1.2%,ranging from
a 43.0% loss to a gain of 9.1%. Mean %EWL was 25.9±3.6%
ranging from an excess weight loss of 76.4% to an excess
weight gain of 21.6% (Figure 1). Four adolescents had net
weight gains, the mean of which was 6.1 ±2.8kg(range0.6–
13.5kg).
Twenty nine (35%) provided bloodwork for evaluation.
There were no diﬀerences in the anthropometric data
between those who came for bloodwork and those who did
not (data not shown). Signiﬁcant improvements in BMI,
weight, WC, systolic BP %ile, CRP, and HDL one year after
LAGB were observed (Table 3) .M e Sr e s o l v e di n1 6o ft h e
adolescents diagnosed at baseline (69.6%; P = .0003). There
werenosigniﬁcantdiﬀerencesin%EWL, %WL,orchange in
BMI between those who had MeS at baseline and those who
did not (data not shown). Resolution of MeS correlated to
%EWL, nearing statistical signiﬁcance (P = .06) but did not
correlate to %WL or BMI (P = NS).
Tables 4 and 5 demonstrate correlations of components
of MeS with parameters of weight change in those with
and without MeS at 6m and 12m post-LAGB. At 6m
post-LAGB, %WL, BMI, and %EWL (Table 4) correlated
signiﬁcantly with WC in those who did not have MeS at
baseline. BMI and %WL also correlated signiﬁcantly with
change in TG and FBS in this cohort. In those with MeS
at baseline, BMI, %EWL, and %WL only correlated with
change in WC (Table 4). One year post-LAGB, %EWL, BMI,
and %WL correlated signiﬁcantly with WC in those who
did not have MeS at baseline (Table 5). %WL and BMI,
correlated signiﬁcantly with change in FBS as well. In those
withMeSatbaseline, %EWL, BMIand %WL correlatedwith
WC and HDL (Table 5).
4. Discussion
This study examined the eﬀects of LAGB on a diverse
population of morbidly obese adolescents with respect to
changesinweightandresolutionofMeS.Ourresultsindicate
that LAGB is eﬀective in most morbidly obese adolescents
for achieving weight loss and decreasing the frequency of
MeS. Similar to other adolescent LAGB series, there were no
intraoperative or postoperative deaths, and the complication
rate was comparable to what has previously been reported
[8–10, 14–19] .O u rs t u d ys h o w e dw e i g h tl o s sa t6 ma n d
12m post-LAGB, which is consistent with results of other
studies, but of smaller magnitude. Post-LAGB weight gain
was observed in 15 of 88 adolescents at 6m post-LAGB
and in 4 of 45 adolescents at 12m post-LAGB. While
Widhalm etal.alsoreported weightgainin4 of7adolescents
post-LAGB, they began gaining at 44m after surgery [17].
Although they did not report adolescents who gained weight
postoperatively, Silberhumer et al. and Angrisani et al. did
describe failure rates of 3 out of 50 at 1-year followup and 5
out of 25 at 5-year followup, respectively, deﬁning failure as
%EWL < 25% [13, 14].
Possible explanations for the insuﬃc i e n tw e i g h tl o s sa n d
weight gain in our subjects include lack of social support,
failure to change eating habits, and failure to incorporate
recommended exercise. Degree of adherence to followup
appointments could further contribute to disappointing
outcomes. Possible reasons for lack of followup may include
diﬃculty in attending appointments due to school, work,
or other obligations; inability to ﬁnance appointments due
to loss of health insurance; satisfaction with weight loss
such that no need was felt to see the medical team;
embarrassment at the lack of weight loss or presence of
weight gain; lack of desire to undergo blood testing and/or
consume glucola for the 2-hour oral glucose tolerance test.
We were unable to provide monetary or other incentives
for attending followup visits and complying with lifestyle
modiﬁcations. Such enticements may have increased our
compliance rate and resulted in even better weight loss
results. Information regarding changes in body composition,6 Journal of Obesity
including percent fat mass, was not obtained during the
study. It is possible that for some adolescents muscle accrual
is occurring but not being accounted for when they step
on the scale. We plan to assess body fat percentage of our
study subjects in future visits in order to better understand
body compositional changes that are occurring with weight
changes. We are also investigating factors relating to subject
compliance in order to understand which adolescents will
succeed post-LAGB, thus enabling us to better screen future
candidates.
There is increasing evidence that resolution of obesity-
related comorbidities such as MeS with weight loss can
be seen in adolescents as it has been in adults [16, 19,
25]. Holterman et al., using the International Diabetes
Federation guidelines, reported a 34% reduction of MeS
in 10 adolescent girls at 6m and a 68% reduction at 9m
post-LAGB [16]. Our data show comparable post-LAGB
improvement with a 56.8% resolution of MeS 6m post-
LAGB and a 69.6% resolution of MeS 12 m post-LAGB.
Both series noted near statistically signiﬁcant improvement
in TG 6m post-LAGB, but this was not sustained at the
12m time point in our subjects. This is likely a reﬂection of
dietarychanges,whichincorporatedmorecarbohydrate-rich
foods and fewer fatty foods. Consistent with Holterman et
al., who saw improvements in systolic BP following LAGB,
we saw signiﬁcant improvement in systolic BP 6m and 12m
post-LAGB. In addition, we saw signiﬁcant improvement in
diastolic BP at the 6m time point that was not sustained
12m after surgery. Change in HDL approached statistical
signiﬁcance 6m post-LAGB and was signiﬁcant one year
following surgery, probably a reﬂection of the increase in
physical activity in our subjects over time.
Studies indicate that 10% WL can lead to resolution of
a number of adiposity-related comorbidities [26]. In our
study, subjects lost only 7.5% WL 6m following surgery,
but this gave them a %EWL of 17.1%. This degree of EWL
was accompanied by a signiﬁcant resolution of MeS in these
subjects,manifestedbysigniﬁcantimprovementinanumber
of components that deﬁne the disease. One year following
surgery, with %WL of 10.9% and %EWL of 25.9%, an even
greater percentage of subjects had resolution of MeS. It is
possiblethereforethatlesserdegreesofWLthanthegenerally
recommended 10% in the morbidly obese population will
result in signiﬁcant health-related improvement and that the
utilization of %EWL to assess co-morbidity risk reduction
may be of beneﬁt in the morbidly obese population.
Similar to the observations of Widhalm et al., we also
observed improvements in CRP, an inﬂammatory biomarker
that independently predicts future vascular events [19].
Decreased CRP has been associated with reductions in
the occurrence of adverse cardiovascular outcomes [27]. In
our adolescents, CRP decreased signiﬁcantly at 6m post-
LAGB and continued to decrease at 12m post-LAGB. This
improvementisimportantsince20.5%ofoursubjectshadat
least three risk factors for cardiovascular disease at baseline,
which included obesity, sedentary lifestyle, dyslipidemia,
elevated BP, impaired glucose tolerance, and impaired FBS.
LAGB-induced weight loss appears to eliminate some of
these risk factors, in addition to reducing CRP levels, all of
which may lead to improved cardiovascular health in this
group of adolescents.
This is one of the ﬁrst studies to date to examine
correlations of MeS components to changes in weight in
adolescents following bariatric surgery. At both 6m and
12m post-LAGB, change in WC was correlated with %EWL,
%WL, and change in BMI, irrespective of MeS status. This is
similartoﬁndingsbyCoppenetal.,whoobservedsigniﬁcant
correlation between weight change and WC following a
75.5% decrease in MeS following 10 weeks of diet-induced
weight loss in a group of 6–19 year old [28]. No relationships
were observed with any other metabolic parameter of MeS in
this study. Our results showed that in those without MeS at
baseline, %WL and change in BMI correlated with change in
FBS and TG 6m post-LAGB, ﬁndings that were not observed
in those who had MeS prior to surgery. Despite weight loss
and improvements in individual components of MeS, no
signiﬁcant relationship existed between these components
and weight loss in those with MeS prior to surgery. This
suggests that another factor may serve as a link between
weight change and MeS components and is relevant only in
those who have the syndrome.
12m following LAGB, %WL and change in BMI con-
tinued to correlate with FBS but not with TG in those
who did not have MeS at baseline. The fact that there
was no signiﬁcant improvement in TG levels 12m post-
LAGB could explain this ﬁnding. Interestingly, in those
who did have MeS at baseline, change in HDL correlated
signiﬁcantly with %EWL and %WL. It is as yet unclear
what the signiﬁcance and implications of these ﬁndings are.
Further studies examining the relationship between MeS
components and weight change will help shed more light
into this matter.
This study is limited by the lack of a control group
undergoing conventional diet and exercise, as was present
in a study by O’Brien et al. [8]. The short-term nature
of our study precludes an assessment of the long-term
impact of LAGB on comorbidities; however, long-term
followup is ongoing with a goal of a total of 5 years
of postsurgical followup. Our study is not unique in its
diﬃculty with ensuring followup [24]. The number of
subjects who presented for followup metabolic evaluation
was less than the total number of subjects who presented
for followup anthropometric assessment. There were no
signiﬁcant diﬀerences in weight change between those who
had laboratory data for evaluation and those who did
not, suggesting that our conclusions from the laboratory
assessmentsmaybeextendedtotheentiregroupateachtime
point.
Our study adds to the limited literature documenting the
eﬀectiveness of LAGB in achieving not only weight loss with
limited adverse eﬀects, but also resolution of comorbidities,
particularly MeS in morbidly obese adolescents. We found
that MeS does not hinder weight loss in our study subjects
and that a number of components of MeS improve with less
than the %WL currently recommended for improvement.
The option of using %EWL as a goal for improvement of
comorbidities in the morbidly obese and obese population
is introduced; further studies into this matter are warranted.Journal of Obesity 7
We show that correlations between parameters of weight
change and components of MeS indeed are diﬀerent between
those with and without MeS prior to undergoing surgical
weight loss. Future research into the implications of these
relationships is necessary. Only continued long-term fol-
lowup can clarify the role of LAGB amongst the various
weight loss treatments available and whether the diagnosis
of MeS alters the response of the individual components of
MeS to weight loss.
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